The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,339K data for 617K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

98 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Cyclic RGD peptidomimetics containing 4- and 5-amino-cyclopropane pipecolic acid (CPA) templates as dualaVß3 anda5ß1 integrin ligands.EBI
University Of Florence
Rational improvement of the affinity and selectivity of integrin binding of grafted lasso peptides.EBI
Philipps-Universit£T Marburg
Targeting integrinsavß3 anda5ß1 with newß-lactam derivatives.EBI
University Of Bologna
Pharmacophoric modifications lead to superpotentavß3 integrin ligands with suppresseda5ß1 activity.EBI
Technische Universit£T M£Nchen
Novel inhibitors of alpha 4 beta 1 integrin receptor interactions through library synthesis and screening.EBI
University Of California
Synthesis and assay of retro-a4ß1 integrin-targeting motifs.EBI
University Of Bologna
Small Macrocycles As Highly Active Integrin?2?1 Antagonists.EBI
Sanofi R & D
Synthesis and in vitro evaluation of a novel radioligand foravß3 integrin receptor imaging: [18F]FPPA-c(RGDfK).EBI
University Hospital Of Geneva
Modulation ofavß3- anda5ß1-integrin-mediated adhesion by dehydro-ß-amino acids containing peptidomimetics.EBI
University Of Bologna
Orally available and efficaciousa4ß1/a4ß7 integrin inhibitors.EBI
Elan Pharmaceuticals
Synthesis and evaluation of 4,5-dihydro-5-methylisoxazolin-5-carboxamide derivatives as VLA-4 antagonists.EBI
Ranbaxy Research Laboratories
Arylsulfonamide pyrimidines as VLA-4 antagonists.EBI
Elan Pharmaceuticals
Biselectivity of isoDGR peptides for fibronectin binding integrin subtypesa5ß1 andavß6: conformational control through flanking amino acids.EBI
Technische Universit£T M£Nchen
Identification of N-acyl 4-(5-pyrimidine-2,4-dionyl)phenylalanine derivatives and their orally active prodrug esters as dual-acting alpha4-beta1 and alpha4-beta7 receptor antagonists.EBI
Hoffmann-La Roche
Identification of N-acyl 4-(3-pyridonyl)phenylalanine derivatives and their orally active prodrug esters as dual actinga4ß1 anda4ß7 receptor antagonists.EBI
Hoffmann-La Roche
A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazolyl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid.EBI
Daiichi Sankyo
Identification of trans-4-[1-[[7-fluoro-2-(1-methyl-3-indolyl)-6-benzoxazolyl]acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid as a potent, orally active VLA-4 antagonist.EBI
Daiichi Sankyo
LDV peptidomimetics equipped with biotinylated spacer-arms: synthesis and biological evaluation on CCRF-CEM cell line.EBI
Universit£
Modeling the molecular basis fora4ß1 integrin antagonism.EBI
Ian Wark Laboratories
Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging.EBI
University Of California
SAR of N-phenyl piperidine based oral integrin alpha5beta1 antagonists.EBI
Jerini
Discovery of orally available integrin alpha5beta1 antagonists.EBI
Jerini
Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3',5'-dichloro-isonicotinoyl) amino]-(l)-phenylalanine (MK-0617), a highly potent and orally active VLA-4 antagonist.EBI
Merck Research Laboratories
Discovery of trans-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid: an orally active, selective very late antigen-4 antagonist.EBI
Daiichi Sankyo
Influence of acid surrogates toward potency of VLA-4 antagonist.EBI
Merck Research Laboratories
Identified a morpholinyl-4-piperidinylacetic acid derivative as a potent oral active VLA-4 antagonist.EBI
Daiichi Pharmaceutical
2,3-Diphenylpropionic acids as potent VLA-4 antagonists.EBI
Kaken Pharmaceutical
Identification of potent and novel alpha4beta1 antagonists using in silico screening.EBI
Biogen
Potent alpha 4 beta 1 peptide antagonists as potential anti-inflammatory agents.EBI
Genentech
Dehydrophenylalanine derivatives as VLA-4 integrin antagonists.EBI
Celltech R&D
Sulphonamide-based small molecule VLA-4 antagonists.EBI
Molecumetics
N-isonicotinoyl-(L)-4-aminophenylalanine derivatives as tight binding VLA-4 antagonists.EBI
Merck Research Laboratories
N-aryl 2,6-dimethoxybiphenylalanine analogues as VLA-4 antagonists.EBI
Merck Research Laboratories
Identification of unique VLA-4 antagonists from a combinatorial library.EBI
Merck Research Laboratories
N-acyl-L-phenylalanine derivatives as potent VLA-4 antagonists that mimic a cyclic peptide conformation.EBI
Hoffmann-La Roche
N-Aroyl-L-phenylalanine derivatives as VCAM/VLA-4 antagonists.EBI
Hoffmann-La Roche
N-(pyrimidin-4-yl) and N-(pyridin-2-yl) phenylalanine derivatives as VLA-4 integrin antagonists.EBI
Celltech R&D
Discovery and evaluation of N-(triazin-1,3,5-yl) phenylalanine derivatives as VLA-4 integrin antagonists.EBI
Celltech R&D
N-Tetrahydrofuroyl-(L)-phenylalanine derivatives as potent VLA-4 antagonists.EBI
Merck Research Laboratories
Isoxazolyl, oxazolyl, and thiazolylpropionic acid derivatives as potent alpha(4)beta(1) integrin antagonists.EBI
Pfizer
Imide and lactam derivatives of N-benzylpyroglutamyl-L-phenylalanine as VCAM/VLA-4 antagonists.EBI
Hoffmann-La Roche
Discovery and evaluation of potent, cysteine-based alpha4beta1 integrin antagonists.EBI
Celltech Chiroscience
N-benzylpyroglutamyl-L-phenylalanine derivatives as VCAM/VLA-4 antagonists.EBI
Hoffmann-La Roche
Discovery of a potent, orally bioavailable pyrimidine VLA-4 antagonist effective in a sheep asthma model.EBI
Elan Pharmaceuticals
Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist.EBI
Merck Research Laboratories
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targetinga5ß1: part 1.EBI
Astrazeneca
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targetinga5ß1: part 2.EBI
Astrazeneca
Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partially modified retro-inverso cyclotetrapeptide mimetics.EBI
Universita Degli Studi Di Bologna
Selective cell adhesion inhibitors: Barbituric acid based alpha4beta7--MAdCAM inhibitors.EBI
Millennium Pharmaceuticals
Synthesis and SAR of pyridazinone-substituted phenylalanine amide alpha4 integrin antagonists.EBI
Johnson & Johnson Pharmaceutical Research & Development
Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues.EBI
Universit£
Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligands.EBI
3-Dimensional Pharmaceuticals
Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agents.EBI
Genentech
Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists.EBI
Merck Research Laboratories
Ultrasmall particle of iron oxide--RGD peptidomimetic conjugate: synthesis and characterisation.EBI
Universit£
Multiple N-methylation by a designed approach enhances receptor selectivity.EBI
Technische UniversitäT MüNchen
Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one scaffolds.EBI
Università
Design and synthesis of a new class of selective integrin alpha5beta1 antagonists.EBI
Jerini
Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective alphavbeta3 inhibitor: design, synthesis, and optimization.EBI
Pfizer
Highly constrained bicyclic VLA-4 antagonists.EBI
Merck Research Laboratories
Convergent, parallel synthesis of a series of beta-substituted 1,2,4-oxadiazole butanoic acids as potent and selective alpha(v)beta3 receptor antagonists.EBI
Pfizer
Ligand binding analysis for human alpha5beta1 integrin: strategies for designing new alpha5beta1 integrin antagonists.EBI
Università
Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core.EBI
Johnson And Johnson Pharmaceutical Research & Development
Rational design and synthesis of novel heparan sulfate mimetic compounds as antiadhesive agents.EBI
Riken Discovery Research Institute
Bioisosteric replacement of anilide with benzoxazole: potent and orally bioavailable antagonists of VLA-4.EBI
Merck Research Laboratories
Synthesis of cinnamic acids and related isosteres as potent and selective alpha v beta 3 receptor antagonists.EBI
Pfizer
Solid-phase synthesis of a small library of 3-phenylthio-3-nicotinyl propionic acid derivatives acting as antagonists of the integrin alphaVbeta3.EBI
Nerviano
Aza-bicyclic amino acid sulfonamides as alpha(4)beta(1)/alpha(4)beta(7) integrin antagonists.EBI
Johnson & Johnson Pharmaceutical Research & Development
Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds.EBI
Pharmaceutical Research Institute
Synthesis and structure-activity relationship of mannose-based peptidomimetics selectively blocking integrin alpha4beta7 binding to mucosal addressin cell adhesion molecule-1.EBI
Technische UniversitäT MüNchen
Improvement of biological activity and proteolytic stability of peptides by coupling with a cyclic peptide.EBI
Kyowa Hakko Kogyo
Nonpeptide RGD antagonists: a novel class of mimetics, the 5,8-disubstituted 1-azabicyclo[5.2.0]nonan-2-one lactam.EBI
University Of Montpellier
N-(3-phenylsulfonyl-3-piperidinoyl)-phenylalanine derivatives as potent, selective VLA-4 antagonists.EBI
Merck Research Laboratories
Thiophene-based vitronectin receptor antagonists.EBI
Shire Biochem
Solid-phase synthesis of dual alpha4beta1/alpha4beta7 integrin antagonists: two scaffolds with overlapping pharmacophores.EBI
Genentech
N-Cycloalkanoyl-L-phenylalanine derivatives as VCAM/VLA-4 antagonists.EBI
Roche Research Center
N-aryl-prolyl-dipeptides as potent antagonists of VLA-4.EBI
Merck Research Laboratories
Focused library approach for identification of new N-acylphenylalanines as VCAM/VLA-4 antagonists.EBI
Roche Research Center
Substituted tetrahydrofuroyl-1-phenylalanine derivatives as potent and specific VLA-4 antagonists.EBI
Merck Research Laboratories
Squaric acid derivatives as VLA-4 integrin antagonists.EBI
Celltech R&D
Substituted N-(3,5-dichlorobenzenesulfonyl)-L-prolyl-phenylalanine analogues as potent VLA-4 antagonists.EBI
Merck Research Laboratories
The discovery of acylated beta-amino acids as potent and orally bioavailable VLA-4 antagonists.EBI
Merck Research Laboratories
The discovery of small molecule carbamates as potent dual alpha(4)beta(1)/alpha(4)beta(7) integrin antagonists.EBI
Merck Research Laboratories
Specific and dual antagonists of alpha(4)beta(1) and alpha(4)beta(7) integrins.EBI
Merck Research Laboratories
Discovery and evaluation of piperidinyl carboxylic acid derivatives as potent alpha(4)beta(1) integrin antagonists.EBI
Bayer
Design and synthesis of potent and selective inhibitors of integrin VLA-4.EBI
Novartis Institute For Biomedical Research
The discovery of sulfonylated dipeptides as potent VLA-4 antagonists.EBI
Merck Research Laboratories
2-Acylimino-3H-thiazoline derivatives: a novel template for platelet GPIIb/IIIa receptor antagonists.EBI
Taisho Pharmaceutical
Discovery and evaluation of potent, tyrosine-based alpha4beta1 integrin antagonists.EBI
Celltech Chiroscience
N-acyl phenylalanine analogues as potent small molecule VLA-4 antagonists.EBI
Roche Research Center
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.EBI
Smithkline Beecham Pharmaceuticals
Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action.EBI
Dupont Pharmaceuticals
Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses.EBI
Biogen
Discovery of potent isoxazoline glycoprotein IIb/IIIa receptor antagonists.EBI
Dupont Pharmaceuticals
Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.EBI
Merck Research Laboratories
Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists.EBI
Telios Pharmaceuticals
Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors.EBI
Merck Research Laboratories